Risk Factors Update Summary
- Accumulated total deficit increased from approximately $298 million to $339 million.
- ACA provisions impacting pharmaceutical industry include changes in Medicaid rebate liability to 23.1%.
- Net loss attributable to common stockholders increased from approximately $38.7 million to $41.5 million.
- Legislative and regulatory changes in healthcare systems could affect future results of operations.
- Cash, cash equivalents, and short-term investments decreased from approximately $105 million to $74 million.
- Number of employees increased from 24 to 32 as of December 31, 2023.
- Working capital decreased from approximately $103 million to $67 million.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1213037&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.